Breaking News

Wall Street Journal Says Its Investigation of 340B Hospitals Raises Questions about Program’s Growth and Purpose

Screenshot of Wall Street Journal article Many Hospitals Get Big Drug Discounts.
The Wall Street Journal's long article today about hospital participation in 340B comes three months after a similar lengthy critique by The New York Times.

A growing number of hospitals that do not qualify for 340B drug discounts as disproportionate share hospitals are enrolling instead under less demanding criteria for rural referral centers—including nationally prominent urban hospitals in metro Boston, Chicago, and Cleveland, The Wall

Read More »

340B Hospitals’ Share of Part B Drug Administration Continues Rising, PhRMA-Funded Study Finds

Image of Infusion drip
New drug industry-funded research found that Part B drug administration continues rising at 340B hospitals and falling at other hospitals and physician offices.

Thirty-five percent of drugs paid for by Medicare Part B in 2021 were administered in 340B hospital outpatient departments, up from 19% in 2012, new research funded by brand drug manufacturers shows.

The share of Part B drugs administered in

Read More »

U.S. Retail Drug Spending Rose 7.8% in 2021, as COVID Eased and Patients Got Care They Postponed

Image of miniature shopping cart and medicine blister packs
Retail prescription drug spending rose by 7.8% in 2021, as COVID-19 eased and patients got care they had been putting off, CMS says.

Retail prescription drug spending in the U.S. shot up 7.8% to $378 billion in 2021, more than double the 3.7% spending growth rate in 2020, as the easing of the COVID-19 pandemic brought a surge in doctor visits and a

Read More »

Extent of 340B’s Impact on Overall Drug Prices Unclear Due to Lack of Data, Study Finds

Image of 340B program study table of contents by Leavitt Partners
Lack of data makes it hard to assess 340B's impact on drug company launch prices and covered entities' uses of 340B savings, researchers at consulting firm Leavitt Partners say.

Lack of data makes it hard to assess the 340B program’s overall impact on drug prices charged by pharmaceutical companies and covered entities, a new study by healthcare consulting and lobbying firm Leavitt Partners concludes.

“We found compelling evidence that

Read More »

340B Hospitals Use Biosimilars Less Than Others, PhRMA-Commissioned Study Finds

graphic image of biosimilar pills depicted equal on a scale
340B hospitals use biosimilar drugs less than other hospitals, a PhRMA-funded study found.

340B hospitals use biosimilar drugs less than other hospitals, which may expose patients to higher out-of-pocket costs, a drug industry funded study concludes.

Pharmaceutical Research and Manufacturers of America released the study last week. Healthcare consulting firm Milliman did the research for

Read More »

Hospital Group Says Survey Shows Drug Companies’ 340B Contract Pharmacy Limits Are Harmful

AHA survey depicting hospitals' annualized revenue losses
Drug companies' 340B contract pharmacy limits are harming 340B hospitals and their patients, the AHA says a new member survey shows.

Drug company actions to limit 340B pricing through contract and specialty pharmacies are harming 340B hospitals and their patients, according to a new American Hospital Association member survey.  

AHA released the results yesterday. More than 300 hospitals were surveyed in April,

Read More »

340B Law Should Be Amended to Include Emergency-Use COVID-19 Drugs, Health Affairs Opinion Article Says

screenshot of Bebtelovimab product page
A screen shot from an HHS video about the monoclonal antibody betelovimab used to treat COVID-19 infection.

The 340B statute should be amended to extend discounts to emergency-use drugs to treat COVID-19 as a first step in rebuilding the COVID-19 safety net, an opinion piece published yesterday in the medical journal Health Affairs says.

The Nov.

Read More »

Law Firm Releases Survey of State Action on 340B Amid Mounting Calls for Congressional Action

Helen Pfister headshot
"The big question for a lot of 340B stakeholders is if Congress is going to step in," Mannatt law firm partner Helen Pfister observed during a Nov. 9 webinar on state action on 340B and mounting pressure on Congress to clarify the 340B program.

Pressure on Congress to clarify the 340B program is reaching unprecedented levels, health care attorneys at the Manatt law firm said during a webinar Wednesday on the future of the program.

Meanwhile, a new survey by the firm showed that

Read More »

As Interest in Legislation Grows, Congressional Research Service Issues Back-to-Back Reports on 340B Program

Congressional Research Service wordmark and logo
The Congressional Research Service issued a summary of the range of policy actions affecting 340B contract pharmacy use in recent years

Congress’ nonpartisan research office has issued a four-page backgrounder on litigation over the 340B contract pharmacy program and a two-pager on the entire drug discount program. They could be a sign that 340B hearings and/or bills are coming.

The Congressional

Read More »

Twice as Many Providers as in May Are Submitting 340B Drug Claims Data to 340B ESP, Pharma Contractor Says

340B ESP infographic
340B ESP says more that 1,000 covered entities—double the number in May—are submitting 340B drug claims data to it to be able to keep dispensing manufacturers’ drugs to patients at multiple contract pharmacies.

More than 1,000 covered entities—double the number in May—are submitting 340B drug claims data to Second Sight Solutions’ 340B ESP platform to be able to keep dispensing manufacturers’ drugs to patients at multiple contract pharmacies, a senior 340B ESP leader

Read More »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer Live